Min-Chan Kim , MD, PhD, Jeong-Hwan Yook , MD, PhD, Han-Kwang Yang , MD, PhD, Hyuk-Joon Lee , MD, PhD, Tae-Sung Sohn , MD, PhD, Woo-Jin Hyung , MD, PhD, Seung-Wan Ryu , MD, PhD, Yukinori Kurokawa , MD, PhD, Young-Woo Kim , MD, PhD, Sang-Uk Han , MD, PhD, Hyung-Ho Kim , MD, PhD, Do-Joong Park , MD, PhD, Wook Kim , MD, PhD, Sang-Il Lee , MD, PhD, Haruhiko Cho , MD, PhD, Gyu-Seok Cho , MD, PhD, Jin-Jo Kim , MD, PhD, Ki-Han Kim , MD, PhD, Moon-Won Yoo , MD, PhD
16 October 2015
The aim of this study was to evaluate the treatment and prognosis of gastric gastrointestinal stromal tumors (GISTs) according to the 7th UICC/AJCC tumor-node-metastasis (TNM) system and the modified National Institutes of Health (NIH) risk classification. The study cohort consisted of 1057 patients with gastric GIST who underwent surgery between January 2000 and December 2007 from 13 institutions in Korea and 2 in Japan. Clinicopathologic characteristics, surgical outcomes, recurrence, and 5-year recurrence-free survival were evaluated.
The mean age of the patients was 58.6 years. Thirty patients (2.8%) had distant metastasis preoperatively. Median tumor size was 4.0 cm. Complete resection (R0 resection) was achieved in 1018 patients (96.3%). Eighty-six patients (8.1%) had postoperative complications, and 2 patients (0.2%) died within 30 days after surgery. According to the 7th UICC/AJCC TNM system, 5-year recurrence-free survival rates were 95% to 99% in stage I, 94.1% in stage II, 74.1% in stage IIIA, 48.6% in stage IIIB, and 50.0% in stage IV patients. On survival analysis of high-risk patients according to the TNM system, the 5-year recurrence-free survival rates were 91.6% in stage II, 74.1% in stage IIIA, and 48.6% in stage IIIB patients. Independent factors of recurrence following surgery for gastric GIST were gender, tumor size, mitotic count, and radicality on multivariate analysis.
The treatment outcome and prognosis of gastric GIST in Korea and Japan seem more favorable compared to those in Western countries. Compared to the modified NIH risk classification, the 7th UICC/AJCC TNM system is more reflective of the 5-year recurrence-free survival of patients with gastric GIST.